Selected characteristics of the study population by cohort (MCCS, NHS, and PLCO)
| . | MCCS23 . | NHS22,25 . | PLCO26 . | |||
|---|---|---|---|---|---|---|
| Cases . | Controls . | Cases . | Controls . | Cases . | Controls . | |
| No. of persons | 55 | 110 | 39 | 71 | 96 | 192 |
| Mean age at blood draw, y (SD) | 59.5 (7.4) | 59.5 (7.4) | 59.4 (6.0) | 58.3 (5.9) | 63.9 (5.2) | 63.8 (5.0) |
| Sex, N (%) | ||||||
| Male | 31 (56.4) | 62 (56.4) | NA | NA | 60 (62.5) | 120 (62.5) |
| Female | 24 (43.6) | 48 (43.6) | 39 (100) | 71 (100) | 36 (37.5) | 72 (37.5) |
| Race, N (%) | ||||||
| White | 55 (100) | 110 (100) | 39 (100) | 71 (100) | 87 (90.6) | 174 (90.6) |
| Black | NA | NA | NA | NA | 4 (4.2) | 8 (4.2) |
| Asian | NA | NA | NA | NA | 2 (2.1) | 4 (2.1) |
| Other | NA | NA | NA | NA | 3 (3.1) | 6 (3.1) |
| Mean BMI at blood draw, kg/m2, (SD) | 27.4 (4.2) | 26.8 (3.9) | 26.1 (4.7) | 25.4 (4.5) | 28.4 (6.0) | 27.5 (4.7) |
| < 18.5, N (%) | 1 (1.8) | NA | 1 (2.6) | NA | NA | 2 (1.0) |
| < 18.5-25, N (%) | 16 (29.1) | 38 (34.6) | 16 (41.0) | 36 (50.7) | 27 (28.1) | 53 (27.6) |
| < 25-30, N (%) | 24 (43.6) | 50 (45.5) | 14 (35.9) | 20 (28.2) | 41 (42.7) | 95 (49.5) |
| 30+, N (%) | 14 (25.5) | 22 (20.0) | 6 (15.4) | 10 (14.1) | 28 (29.2) | 40 (20.8) |
| Missing, N (%) | NA | NA | 2 (5.1) | 5 (7.0) | NA | 2 (1.0) |
| Type of blood sample, N (%) | ||||||
| Serum | NA | NA | NA | NA | NA | NA |
| Plasma, heparin | 55 (100) | 110 (100) | 39 (100) | 71 (100) | 96 (100) | 192 (100) |
| Plasma, EDTA | NA | NA | NA | NA | NA | NA |
| Plasma, sodium citrate | NA | NA | NA | NA | NA | NA |
| Fasting status, N (%) | ||||||
| Fasting | 42 (76.4) | 84 (76.4) | 27 (69.2) | 56 (78.9) | NA | NA |
| Not fasting | 13 (23.6) | 26 (23.6) | 12 (30.8) | 15 (21.1) | 96 (100) | 193 (100) |
| Mean blood draw to diagnosis, y (range) | 8.2 (1.1-16.8) | 8.2 (1.2-16.8) | 9.4 (1.5-16.0) | 9.8 (2.8-16.1) | 6.4 (1.2-12.3) | 6.4 (1.2-12.5) |
| ≤ 3, N (%) | 6 (10.9) | 10 (9.1) | 2 (5.3) | 1 (1.9) | 9 (9.4) | 17 (8.9) |
| 4- ≤ 6, N (%) | 14 (25.5) | 30 (27.3) | 6 (15.8) | 10 (18.9) | 37 (38.5) | 75 (39.1) |
| > 6, N (%) | 35 (63.6) | 70 (63.6) | 30 (79.0) | 42 (79.3) | 50 (52.1) | 100 (52.1) |
| Mean peripheral blood biomarker concentrations (SD) | ||||||
| IGF-1, ng/mL | 158.9 (52.9) | 161.5 (50.2) | 151.5 (51.2) | 151.3 (47.4) | 159.9 (58.5) | 158.1 (52.0) |
| IGFBP-3, ng/mL | 4777 (1404) | 4872 (1170) | 5300 (1299) | 5327 (1293) | 4708 (1285) | 4660 (1069) |
| IGF-1/IGFBP-3 molar ratio | 0.1 (0.03) | 0.1 (0.03) | 0.1 (0.02) | 0.1 (0.03) | 0.1 (0.03) | 0.1 (0.03) |
| IGFBP-1, ng/mL | 34.4 (23.6) | 25.4 (15.2) | 20.9 (13.1) | 24.4 (15.4) | NA | NA |
| C-peptide, ng/mL | 1.7 (1.2) | 1.5 (0.8) | 2.2 (1.4) | 2.5 (1.7) | 2.8 (1.8) | 3.0 (2.5) |
| CRP, mg/L | 3.1 (7.8) | 2.3 (3.0) | 2.6 (3.8) | 2.8 (3.9) | 3.4 (4.8) | 3.7 (6.0) |
| IL-6, pg/mL | 1.7 (1.4) | 2.4 (3.6) | 2.2 (2.9) | 1.6 (1.5) | 2.3 (1.7) | 2.4 (2.3) |
| sIL6R, pg/mL | 42 252 (11 293) | 41 908 (10 234) | 42 793 (10 563) | 40 909 (10 879) | 43 495 (11 683) | 41 909 (10 816) |
| . | MCCS23 . | NHS22,25 . | PLCO26 . | |||
|---|---|---|---|---|---|---|
| Cases . | Controls . | Cases . | Controls . | Cases . | Controls . | |
| No. of persons | 55 | 110 | 39 | 71 | 96 | 192 |
| Mean age at blood draw, y (SD) | 59.5 (7.4) | 59.5 (7.4) | 59.4 (6.0) | 58.3 (5.9) | 63.9 (5.2) | 63.8 (5.0) |
| Sex, N (%) | ||||||
| Male | 31 (56.4) | 62 (56.4) | NA | NA | 60 (62.5) | 120 (62.5) |
| Female | 24 (43.6) | 48 (43.6) | 39 (100) | 71 (100) | 36 (37.5) | 72 (37.5) |
| Race, N (%) | ||||||
| White | 55 (100) | 110 (100) | 39 (100) | 71 (100) | 87 (90.6) | 174 (90.6) |
| Black | NA | NA | NA | NA | 4 (4.2) | 8 (4.2) |
| Asian | NA | NA | NA | NA | 2 (2.1) | 4 (2.1) |
| Other | NA | NA | NA | NA | 3 (3.1) | 6 (3.1) |
| Mean BMI at blood draw, kg/m2, (SD) | 27.4 (4.2) | 26.8 (3.9) | 26.1 (4.7) | 25.4 (4.5) | 28.4 (6.0) | 27.5 (4.7) |
| < 18.5, N (%) | 1 (1.8) | NA | 1 (2.6) | NA | NA | 2 (1.0) |
| < 18.5-25, N (%) | 16 (29.1) | 38 (34.6) | 16 (41.0) | 36 (50.7) | 27 (28.1) | 53 (27.6) |
| < 25-30, N (%) | 24 (43.6) | 50 (45.5) | 14 (35.9) | 20 (28.2) | 41 (42.7) | 95 (49.5) |
| 30+, N (%) | 14 (25.5) | 22 (20.0) | 6 (15.4) | 10 (14.1) | 28 (29.2) | 40 (20.8) |
| Missing, N (%) | NA | NA | 2 (5.1) | 5 (7.0) | NA | 2 (1.0) |
| Type of blood sample, N (%) | ||||||
| Serum | NA | NA | NA | NA | NA | NA |
| Plasma, heparin | 55 (100) | 110 (100) | 39 (100) | 71 (100) | 96 (100) | 192 (100) |
| Plasma, EDTA | NA | NA | NA | NA | NA | NA |
| Plasma, sodium citrate | NA | NA | NA | NA | NA | NA |
| Fasting status, N (%) | ||||||
| Fasting | 42 (76.4) | 84 (76.4) | 27 (69.2) | 56 (78.9) | NA | NA |
| Not fasting | 13 (23.6) | 26 (23.6) | 12 (30.8) | 15 (21.1) | 96 (100) | 193 (100) |
| Mean blood draw to diagnosis, y (range) | 8.2 (1.1-16.8) | 8.2 (1.2-16.8) | 9.4 (1.5-16.0) | 9.8 (2.8-16.1) | 6.4 (1.2-12.3) | 6.4 (1.2-12.5) |
| ≤ 3, N (%) | 6 (10.9) | 10 (9.1) | 2 (5.3) | 1 (1.9) | 9 (9.4) | 17 (8.9) |
| 4- ≤ 6, N (%) | 14 (25.5) | 30 (27.3) | 6 (15.8) | 10 (18.9) | 37 (38.5) | 75 (39.1) |
| > 6, N (%) | 35 (63.6) | 70 (63.6) | 30 (79.0) | 42 (79.3) | 50 (52.1) | 100 (52.1) |
| Mean peripheral blood biomarker concentrations (SD) | ||||||
| IGF-1, ng/mL | 158.9 (52.9) | 161.5 (50.2) | 151.5 (51.2) | 151.3 (47.4) | 159.9 (58.5) | 158.1 (52.0) |
| IGFBP-3, ng/mL | 4777 (1404) | 4872 (1170) | 5300 (1299) | 5327 (1293) | 4708 (1285) | 4660 (1069) |
| IGF-1/IGFBP-3 molar ratio | 0.1 (0.03) | 0.1 (0.03) | 0.1 (0.02) | 0.1 (0.03) | 0.1 (0.03) | 0.1 (0.03) |
| IGFBP-1, ng/mL | 34.4 (23.6) | 25.4 (15.2) | 20.9 (13.1) | 24.4 (15.4) | NA | NA |
| C-peptide, ng/mL | 1.7 (1.2) | 1.5 (0.8) | 2.2 (1.4) | 2.5 (1.7) | 2.8 (1.8) | 3.0 (2.5) |
| CRP, mg/L | 3.1 (7.8) | 2.3 (3.0) | 2.6 (3.8) | 2.8 (3.9) | 3.4 (4.8) | 3.7 (6.0) |
| IL-6, pg/mL | 1.7 (1.4) | 2.4 (3.6) | 2.2 (2.9) | 1.6 (1.5) | 2.3 (1.7) | 2.4 (2.3) |
| sIL6R, pg/mL | 42 252 (11 293) | 41 908 (10 234) | 42 793 (10 563) | 40 909 (10 879) | 43 495 (11 683) | 41 909 (10 816) |
Percentages and counts may not sum to the total because of rounding and/or missing data.
NA indicates not applicable.